Physician profile
Eric A Wien
NPI 1952806804
$1,372.71
in general payments reported to CMS, 2019-2025
17 companies · $525 in 2025
The $525 reported for 2025 was less than what a typical Hepatology provider received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $271 · 2023: $113 · 2024: $464 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,101.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $225.48 | 2023-2025 | Mavyret |
| Glaxosmithkline, LLC. | $183.92 | 2022-2023 | |
| Madrigal Pharmaceuticals | $160.99 | 2025 | Rezdiffra |
| Mallinckrodt Hospital Products INC. | $146.25 | 2022 | |
| Intercept Pharmaceuticals, INC. | $144.34 | 2024 | |
| Novo Nordisk INC | $122.65 | 2025 | Wegovy |
| Boston Scientific Corporation | $88.35 | 2024 | Acquire |
| Orphalan INC | $62.65 | 2024-2025 | Cuvrior |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.57 | 2024-2025 | Xifaxan |
| Janssen Biotech, INC. | $31.40 | 2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $28.90 | 2024 | Entyvio |
| Merck Sharp & Dohme LLC | $25.05 | 2024 | Dificid |
| Qol Medical, LLC | $24.01 | 2024 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $23.85 | 2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.87 | 2023 | Cyltezo |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $17.70 | 2023 | |
| Braintree Laboratories, INC. | $14.73 | 2024 | Sutab |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Wien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.